Update Breast Cancer 2020 Part 3 – Early Breast Cancer

Huober, Jens; Schneeweiß, Andreas; Hartkopf, Andreas D.; Müller, Volkmar; Lux, Michael P.; Janni, Wolfgang; Ettl, Johannes; Belleville, Erik; Thill, Marc; Fasching, Peter A.; Kolberg, Hans‐Christian; Schulmeyer, Carla E.; Welslau, Manfred; Overkamp, Friedrich; Tesch, Hans; Fehm, Tanja; Lüftner, Diana; Schütz, Florian; Wöckel, Achim

doi:10.1055/a-1270-7208

Cited by 12 publications

(13 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diese Übersichtsarbeit fasst die neuesten Studienergebnisse zur Prävention und Therapie von Patientinnen mit Mammakarzinom in frühen Krankheitsstadien zusammen. Die Entwicklungen der letzten Jahre zeigen, dass Neuerungen in der Behandlung mit hoher Geschwindigkeit in den klinischen Alltag eingeführt werden 1 , 2 , 3 , 4 , 5 , 6 . Berücksichtigt wurden Vollpublikationen und Präsentationen der aktuellen relevanten Krebs- und Brustkrebskongresse wie z.…”

Section: Einführungunclassified

“…This review summarises the latest study outcomes in prevention and treatment of patients with early-stage breast cancer. Developments in recent years have shown that treatment innovations enter clinical practice at a rapid pace 1 , 2 , 3 , 4 , 5 , 6 . This paper includes full publications and presentations at the current major cancer and breast cancer meetings such as ESMO (European Society for Medical Oncology) 2020 and SABCS (San Antonio Breast Cancer Symposium) 2020.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Update Breast Cancer 2021 Part 1 – Prevention and Early Stages

Stickeler

Aktas

Behrens

et al. 2021

Geburtshilfe Frauenheilkd

Self Cite

View full text Add to dashboard Cite

This review summarises not only the latest evidence on prevention, but also the current research on the treatment of early-stage breast cancer patients. Recent years have seen a growing body of evidence on the risk of high- and moderate-penetrance breast cancer susceptibility genes. A large international consortium has now been able to further refine the answer to the question of the significance of the so-called panel genes. Moreover, the data on treatment selection regarding endocrine efficacy and the decision for or against chemotherapy have also been advanced markedly. There is also new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/6) inhibitors, which are standard in first-line treatment in patients with metastatic HER2-negative, hormone receptor-positive (HR+) breast cancer. For other therapies such as immune checkpoint inhibitors, which have successfully improved the rate of pathologic complete response (pCR) in neoadjuvant treatment settings for patients with triple-negative breast cancer (TNBC), there is a growing understanding of the quality of life and side effects. This is especially important in situations where patients could possibly be cured without such a regimen.

show abstract

Section: Einführungunclassified

Section: Introductionmentioning

confidence: 99%

Update Breast Cancer 2021 Part 1 – Prevention and Early Stages

Stickeler

Aktas

Behrens

et al. 2021

Geburtshilfe Frauenheilkd

Self Cite

View full text Add to dashboard Cite

show abstract

“…Des Weiteren wird von einer großen gepoolten Analyse in Bezug auf die Fertilität und Schwangerschaften nach einer Brustkrebserkrankung berichtet. Diese Art der Therapieeinflüsse auf die Lebensqualität spielen bei immer besser werdenden Therapien, die in den letzten Jahren etabliert wurden 1 , 2 , 3 , 4 , 5 , 6 , eine besondere Rolle. Berücksichtigt werden aktuelle Vollpublikationen und Präsentationen der letzten onkologischen und senologischen Kongresse wie z.…”

Section: Einführungunclassified

“…It also reports a large pooled analysis of fertility and pregnancy after breast cancer treatment. This type of therapeutic impact on quality of life plays a special role in the ever-improving therapies established in recent years 1 , 2 , 3 , 4 , 5 , 6 . This paper considers full publications and presentations at the current major cancer and breast cancer meetings such as ESMO (European Society for Medical Oncology) 2020 and SABCS (San Antonio Breast Cancer Symposium) 2020.…”

Section: Introductionmentioning

confidence: 99%

Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers

Ditsch

Stickeler

Behrens

et al. 2021

Geburtshilfe Frauenheilkd

Self Cite

View full text Add to dashboard Cite

This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to immune checkpoint inhibitors in metastasised breast cancer, the recent discussion has centred on the best candidate for combined chemotherapy. The oral taxanes could become a new type of oral chemotherapies. There is a growing body of data on biomarkers for the use of CDK4/6 inhibitors, which could also signify further development for other molecular subtypes. New substances have been developed for metastatic HER2+ breast cancer that still result in good remission even after massive prior treatment and/or cerebral metastasis. Similarly, knowledge is growing about targeted therapies with antibody-drug conjugates (ADC) against Trop-2, which could bolster our therapeutic armoury in triple-negative breast cancer (TNBC). In addition, the clinical focus is on understanding how to maintain fertility after breast cancer treatment. Here, pooled analyses provide new insights.

show abstract

“…Women with a high PMD (>75%) compared to women with a low PMD (<5%) have an up to fivefold increase in the risk of BC [ 4 , [13] , [14] , [15] ]. Although the impact of MD on the risk of BC is well known, its influence on the prognosis is still controversial.…”

Section: Introductionmentioning

confidence: 99%

Mammographic density and prognosis in primary breast cancer patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose Mammographic density (MD) is one of the strongest risk factors for breast cancer (BC). However, the influence of MD on the BC prognosis is unclear. The objective of this study was therefore to investigate whether percentage MD (PMD) is associated with a difference in disease-free or overall survival in primary BC patients. Methods A total of 2525 patients with primary, metastasis-free BC were followed up retrospectively for this analysis. For all patients, PMD was evaluated by two readers using a semi-automated method. The association between PMD and prognosis was evaluated using Cox regression models with disease-free survival (DFS) and overall survival (OS) as the outcome, and the following adjustments: age at diagnosis, year of diagnosis, body mass index, tumor stage, grading, lymph node status, hormone receptor and HER2 status. Results After median observation periods of 9.5 and 10.0 years, no influence of PMD on DFS ( p = 0.46, likelihood ratio test (LRT)) or OS ( p = 0.22, LRT), respectively, was found. In the initial unadjusted analysis higher PMD was associated with longer DFS and OS. The effect of PMD on DFS and OS disappeared after adjustment for age and was caused by the underlying age effect. Conclusions Although MD is one of the strongest independent risk factors for BC, in our collective PMD is not associated with disease-free and overall survival in patients with BC.

show abstract

Update Breast Cancer 2020 Part 3 – Early Breast Cancer

Cited by 12 publications

References 73 publications

Update Breast Cancer 2021 Part 1 – Prevention and Early Stages

Update Breast Cancer 2021 Part 1 – Prevention and Early Stages

Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers

Mammographic density and prognosis in primary breast cancer patients

Contact Info

Product

Resources

About